Inclusion criteria: - Tissue from an archived or fresh tumor sample - A peripheral blood buffy coat sample is required for CLL/SLL. - Patient has mantle cell lymphoma (MCL), follicular lymphoma (FL), or chronic lymphocytic leukemia (CLL)/SLL - Patient > or = 18 years old - Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 - Adequate white blood cells and hemoglobin - Good kidney and liver function - Fasting glucose < 160 mg/dL - No other malignancy - Use of adequate birth control Exclusion criteria: - Treatment with cytotoxic chemotherapy, biologic agents, investigational therapies within 4 weeks, or nitrosoureas or mitomycin C within 6 weeks of study enrollment - Treatment with a small-molecule kinase inhibitor within 2 weeks, or 5 half lives of the drug or its active metabolites (whichever is longer) of study enrollment - Prior treatment with a PI3K, mTOR, or Akt inhibitor. Prior treatment of MCL with temsirolimus is permitted in patients enrolled from countries where it is licensed for this indication. - Radiation therapy within 2 weeks of enrollment - Autologous stem cell transplantation within 16 weeks of enrollment - Prior allogeneic transplantation - Central nervous system or leptomeningeal involvement - Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (anti-HCV) serology The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.